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Matrix metalloproteinases, in particular the gelatinases MMP-2 and MMP-9, have received great attention in recent years as putative
tumour markers for clinical applications. The main reason for the observed interest is their easy detection in body fluids. Moreover,
recent evidence has shown multiple functions of MMPs, rather than simply degrading ECM, which include the mobilisation of growth
factors and processing of surface molecules. Several authors have reported increased levels of MMPs in a number of cancers, but
clinical correlations in breast cancer are still fragmentary. Thus, the aim of the present research was to investigate the activity levels of
circulating gelatinases in the sera of breast cancer patients by means of zymographic analysis, and correlate data with
clinicopathological parameters. In all, 80 patients and 22 healthy volunteers were involved in this study. Sera were obtained prior to
surgery. The clinical variables were: grading of tumours, tumour size, lymph node involvement, tumour staging, oestrogen and
progesterone receptor levels (76 out of 80 cases), and c-erbB-2 levels (46 cases). The densitometric measures of MMP-2 and MMP-9
activity levels indicated that the average values of both gelatinase activities were significantly higher in breast cancers than in control
sera (Po0.0001). In addition, our analysis showed for the first time that elevated activity levels of both gelatinases correlated only
with c-erbB-2 overexpression (P¼0.0273 for MMP-2 and P¼0.0075 for MMP-9). An inverse correlation was observed with regard
to oestrogen receptor expression (P¼0.0075 for MMP-2 and P¼0.0273 for MMP-9). Moreover, a borderline inverse correlation
was observed between the activity levels of both enzymes and nuclear grade (P¼0.0511 for MMP-2 and P¼0.0794 for MMP-9). In
conclusion, the present data suggest that serum measures of MMP’s activity may have diagnostic value for discriminating subgroups of
breast cancer patients and support the hypothesis that ERBB2 amplification and/or overexpression enhance signalling pathways that
may lead to increased production of gelatinases in c-erbB-2 positive breast cancers with higher metastatic potentialities.
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Tumours arise from multiple genetic alterations, which affect
primarily cell proliferation. A crucial difference between benign
and malignant tumours is that the first remain encapsulated for
undefined periods of time and do not form metastases, while the
second acquire the ability to invade the underlying basal lamina
and its adjacent stroma, which in normal tissues do not show
passageways for cells of epithelial origin.
A critical event, during progression of malignant carcinomas, is
the invasive growth of neoplastic cells into the host tissues: this
involves the onset of a number of complex interactions occurring
at the tumour–host interface, including an extensive remodelling
of the extracellular matrix (ECM). Degradation of the ECM
requires the concerted action of a number of extracellular
enzymes.
Several enzyme families are known to be involved in extra-
cellular proteolysis. These include serine proteases (e.g. Blasi and
Carmeliet, 2002; Diamandis and Yousef, 2002), matrix metallo-
proteinases (MMPs; reviewed by Somerville et al, 2003), and
disintegrin-metalloproteinase (ADAMs: A Disintegrin And Metal-
loproteinase Domain; reviewed by O’Shea et al, 2003).
The MMP family is one of the most studied, since many
members of the group have been recognised as involved in cancer
invasion and metastasis. Recently, MMPs have been the object of
renewed interest due to the additional roles attributed to their
functions, for example, growth factor mobilisation and the
processing of surface molecules (cf. Somerville et al, 2003). At
present, there are 23 human MMP genes, which are structurally
similar to each other, indicating that they evolved by duplication of
a common ancestral gene followed by divergent evolution (Moura-
da-Silva et al, 1996). Based on substrate specificity and domain
organisation, the MMPs have been tentatively divided into four
main groups: interstitial collagenases, gelatinases, stromelysins
and membrane-type MMPs. Most MMPs are secreted as proen-
zymes and are organised into distinct structural domains, with
some differences in domain composition and number (Nagase and
Woessner, 1999).
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other MMPs in that they have three tandem fibronectin type II
repeats within the amino terminus of the catalytic module that
mediates gelatin binding (Murphy et al, 1994). Moreover, these
two enzymes interact with physiological inhibitors (respectively,
TIMP-2 and TIMP-1) even if they are in the proenzymatic form
(Overall et al, 1999). Traditionally, MMP-2 and MMP-9 have been
correlated with the invasive stage of carcinomas, because of their
ability to degrade type IV collagen, a major constituent of
basement membranes (Stetler-Stevenson, 1990). More recent
evidence suggests that MMP-2 and MMP-9 may also be involved
in breast cancer initiation and growth through complex interac-
tions with the main oncogenes and tumour-suppressor genes
involved in the early stage of tumorigenesis (Duffy et al, 2000;
Leeman et al, 2003, for reviews). For example, transfection of MCF-
10A breast cancer cells with either c-erbB-2 or c-ras resulted in
increased expression of MMP-2 (Giunciuglio et al, 1995), whereas
transfection of MCF-7 cells with the ets gene PEA-3 led to
increased production of MMP-9 (Kaya et al, 1996). Due to the key
role of MMPs in tumorigenesis, several authors have proposed
MMP-2 and or MMP-9 as useful prognostic markers (i.e. Duffy,
1996). Recent work on breast cancer patients has suggested that
MMP-2 negativity may be linked with a favourable prognosis in
node-negative breast carcinoma (Hirvonen et al, 2003) and that
high activity levels of plasma MMP-9 in breast cancer patients are
associated with a worst overall survival rate (Ranuncolo et al,
2003). Thus, the present research was conducted with the following
objectives: (1) to support the diagnostic value of MMP-2 and
MMP-9 in breast cancer using a highly sensitive zymographic
method; (2) to determine the possible association of activity levels
of serum forms of MMP-2 and MMP-9 with the current clinical
parameters; and (3) to perform the first univariate analysis
including c-erbB-2, a candidate marker of tumour aggressiveness,
at present in course of validation.
In the present study, we examined 80 patients with breast cancer
and no detectable metastases. In all, 22 sera samples from healthy
donors were used as control specimens. To assess possible
correlations between the serum levels of MMP-2 and MMP-9 and
the stage of the disease, the following clinical parameters were
utilised: tumour size, lymph node involvement, tumour stage,
histological grading, oestrogen receptor (ER) levels (76 out of 80
cases), progesterone receptor (PR) levels (76 cases), c-erbB-2 levels
(46 cases). The statistical analyses have shown a significant
increase of activity levels of both MMP-2 and MMP-9 in the sera of
breast cancer patients compared with control sera. The correlation
analyses indicated a significant association between high activity
levels of both enzymes and c-erbB-2 overexpression.
MATERIALS AND METHODS
Sample collection
A total of 80 patients (of which one Tis, 52 T1, 25 T2, two T3)
diagnosed with breast carcinoma but without clinically apparent
metastases were involved in this study. Sera were obtained prior to
surgery, according to the ethical standards, with informed consent
of patients at the Maddalena Hospital. Native serum was prepared
using plastic tubes without coagulation accelerators, to prevent the
release of gelatinases during platelet activation (Fernandez-Patron
et al, 1999). Tubes were centrifuged at 1600g for 10min, 30min
after blood collection. For each sample, determination of protein
concentration was performed using the method of Bradford
(1976). Sera were aliquoted and stored at  801C until used. Each
aliquot was used only once in order to prevent enzyme activation
due to freeze–thawing processes. For all patients, the histological
diagnosis and the stage of cancer were established by assessment
on paraffin sections at diagnostic laboratory of the Maddalena
Hospital. Evaluation of oestrogen receptor (ER) and progesterone
receptor (PR) was performed by immunohistochemistry using
monoclonal antibodies from Dako Corporation (USA). c-erbB-2
expression levels were evaluated using the HercepTest assay
(semiquantitative immunocytochemical assay), with scoring of 0
or 1þ for normal levels of expression and 2þ or 3þ for
overexpression (DakoCytomation, DK). Control sera (n¼22) were
taken from healthy volunteers.
Gelatin zymography
Gelatin zymography was performed for both healthy control and
cancer patients sera as follows: gels (SDS–PAGE, 7.5%) were
copolymerised with gelatin (0.1%) (Sigma-Aldrich). For each
sample, 28mg of total serum protein was loaded. Electrophoresis
was carried out using the minigel slab apparatus Mini Protean 3
(Biorad) at a constant voltage of 150V, until the dye reached the
bottom of the gel. Following electrophoresis, gels were washed in
renaturation buffer (2.5% Triton X-100 in 50mM Tris–HCl (pH
7.5)) for 1h in an orbital shaker. Then the zymograms were
incubated for 18h at 371C in incubation buffer (0.15 M NaCl, 10mM
CaCl2, 0.02% NaN3 in 50mM Tris–HCl (pH 7.5)). Gels were then
stained with Coomassie blue and destained with 7% methanol and
5% acetic acid. Areas of enzymatic activity appeared as clear bands
over the dark background.
Quantification of enzymatic activity
Following zymography, the degree of gelatin digestion was
quantified using a Sharp JX-330 scanner equipped with a
transparency option interfaced to an IBM PC. Gels were scanned
using Image-master software, version 1.2 for DOS (Pharmacia
Biotech), in a grey scale mode at 169mm pixel size and 1250–1650
(X–Y) pixel count, using the autodensity feature on a scale ranging
from 0 (clear) to 255 (opaque). The image was digitally inverted, so
that the integration of bands was reported as positive values. The
pixel density was determined after background subtraction and
used to calculate the integrated density of a selected band. Values
of integrated density were reported in volume units of pixel
intensity per mm
2. The integrated density of each band is reported
as the mean of three different measurements of the same gel for
each sample run in triplicate.
Statistical analysis
For each group of subjects, data derived from zymographic
quantification of activity of MMP-2 and MMP-9 were plotted using
MS Excel software. Statistical analyses were performed using both
MS Excel and Graph Pad Prism 4 (demo) software (for correlation
analysis). Fitness of data to normal distribution was assessed using
the method of Kolmogorov and Smirnov. This normality test
quantifies the discrepancy between the examined distributions of
data and an ideal Gaussian distribution; the test returns a P-value
which is considered acceptable for values greater than 0.05. For all
the distributions examined (i.e. activity levels of MMP-2 and
MMP-9 in control and affected subjects), the test confirmed their
fitness with a normal distribution. In order to estimate the
significance of differences between cancer patients and control
subjects, unpaired Student’s T-test (with Welch’s correction) was
applied. Correlation of MMP-2 and MMP-9 activity levels with
clinicopathological variables for breast cancer patients was
performed using the Pearson correlation test. In all cases, data
were considered significant for values of Po0.05.
Ion exchange chromatography (batch procedure)
DEAE sephacryl has been used to prefractionate sera from breast
cancer patients in order to reach a final purification of gelatinases.
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(50mM Tris/HCl, 0.8% Brij-35 (pH 8)). The resin was rinsed
thoroughly in the same buffer. Then, the sample and resin were
placed in a tube and mixed for 1h at 41C with gentle inversion. At
the end, resin was briefly centrifuged in order to recover the
supernatant (unbound fraction) and successive washes with
equilibration buffer were performed in order to remove all
unbound proteins. All the steps were monitored by measuring
A280 using an Eppendorff biophotometer. Two intermediate
washes with 50mM Tris/HCl (pH 8) were performed to eliminate
detergent from the system. The resin was mixed at 41C with the
elution buffer (150mM NaCl and 50mM Tris/HCl (pH 8)) for
15min, and then centrifuged to obtain the supernatant (bound
fraction). Elution passages were repeated until A280 values near to
zero, in order to elute all bound proteins. Finally, both bound and
unbound fractions were dialysed against MilliQ water at 41C.
Zymography showed the presence of gelatinases only in bound
fractions.
Affinity chromatography (gelatin sepharose with batch
procedure)
Lyophilised bound protein fractions from DEAE chromatography
were solubilised in equilibration buffer (50mM Tris/HCl, 1 M NaCl
pH 7.5). After resuspension, the sample was added to resin and
mixed at 41C for 3h. The resin was briefly centrifuged and then
washed with equilibration buffer to eliminate all unbound
proteins. Elution of gelatinases was accomplished by using a
10% DMSO solution; fractions were then dialysed against MilliQ
water for lyophilisation and Western blotting analysis.
Western blotting
After electrophoresis, proteins were electrotransferred on nitro-
cellulose membranes (Amersham) using the following transfer
buffer: 25mM Tris, 190mM glycine and 20% methanol. Protein
transfer was performed at 50V for 1h at 41C. Following transfer,
the nitrocellulose membrane was stained using Ponceau Red (0.2%
Ponceau Red, 3% TCA) and destained with milliQ water. Blocking
of the membrane was achieved using 5% nonfat milk in TTBS (pH
7.6). The primary antibody was incubated overnight at 41Ci n1 %
nonfat milk in TTBS. The antibodies used were purchased from
Calbiochem (Ab-3 for anti-MMP-2 and Ab-7 for anti-MMP-9).
Following incubation, the filter was washed six times for 5min to
remove the unbound antibody. Then the membrane was incubated
with horseradish-peroxidase-conjugated antibody diluted 1:3000
in 1% nonfat milk in TTBS for 1h at room temperature. After
secondary antibody incubation, the membrane was washed six
times for 5min with TTBS. The filter was then incubated with
luminescent substrate (Supersignal West Pico Pierce) and exposed
to an appropriate film (Amersham).
Inhibition assays
Zymograms of both breast cancer and healthy subjects sera were
incubated with the described incubation buffer, added with
chemical inhibitors of MMPs (EDTA 20mM or 1,10 phenantroline
10mM). Following incubation, at 371C for 18h, gels were stained
with Coomassie blue.
RESULTS
Gelatin zymography
Sera from all subjects, both affected and healthy ones, were
subjected to gelatin zymography to determine the relative levels of
activity attributable to pro-MMP-2 and pro-MMP-9. Figure 1
shows a panel of zymograms from healthy and pathologic subjects,
randomly selected from the collection of our samples, run in
parallel with purified standards of pro-MMP-2 and pro-MMP-9,
and a representative Western blot of purified gelatinases revealed
with anti-MMP-2 and anti-MMP-9 monoclonal antibodies. The
majority of breast cancer sera show stronger intensity of
gelatinolytic bands for both the proenzymatic forms of MMP-2
(72kDa) and MMP-9 (92kDa) when compared with control sera.
Moreover, most breast cancer sera display two lytic bands of 200
and 116kDa, respectively, absent in the majority of the control sera
assayed. These two lytic forms are comparable to those previously
detected in colon carcinoma sera (Pucci-Minafra et al, 2001) and
identified as MMP-9 dimers (the 220kDa) and as MMP-9/TIMP1
complex (the 116kDa).
Identification of gelatinolytic activities
The nature of lytic bands observed in zymograms was further
confirmed by both inhibition and immunodetection assays.
Selective inhibitors of MMPs excluded the presence of gelatinolytic
activities due to serine or cysteine proteinases. Incubation of the
zymograms with 20mM EDTA or 1,10 phenanthroline inhibited all
the gelatinolytic activities of serum samples from both patients and
volunteers (data not shown).
The immunologic detection of both enzymes was performed by
Western blotting with monoclonal antibodies against MMP-2 and
MMP-9, on purified gelatinases (described in Materials and
methods) from serum samples. The antibodies recognised the
proforms of both enzymes in purified sera of breast cancer patients
(cf. Figure 1B), but not other forms corresponding to the higher
molecular weight lytic bands.
Quantitative analysis of gelatinolytic activity
Following gelatin zymography, gels containing samples run in
triplicate were subjected to densitometric analysis to quantify the
relative activity levels of the two gelatinases. Densitometric data in
OD were then normalised for 1mg of total serum proteins and
plotted in graph using MS Excel software. The Student’s T-test
(with Welch’s correction) was applied in order to compare the
differences between the two groups. As shown in Figure 2, the
average activity values of both pro-MMP-2 and -9 are significantly
higher in breast cancer sera vs the control sera (Po0.0001). In
detail, the basic statistical features describing differences in
enzyme activity levels between breast cancer patients (BC) and
control group (C) were the following:
MMP-9: mean¼412.3
BC vs 141.7
C; median¼347
BC vs 124.5
C;
s.d.¼239
BC vs 65.59
C
MMP-2: mean¼320.1
BC vs 160.7
C; median¼260
BC vs 154.5
C,
s.d.¼168.3
BC vs 45.82
C.
220
116
92
72
MW AB C D
Figure 1 Panel of representative gelatin zymograms of sera from breast
cancer patients and healthy subjects. (A) Standards of purified pro-MMP-2
(72kDa) and pro-MMP-9 (92kDa); (B) Western blotting of pro-MMP-2
and pro-MMP-9 from breast cancer sera; (C) sera of breast cancer patients;
(D) sera of healthy subjects.
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parameters
In order to assess the possible correlations between levels of
gelatinase activity and tumour stage, statistical analysis was
performed using Pearson correlation. The variables considered
for this analysis were: grading of tumours, tumour size, lymph
node involvement, tumour staging (following AJCC guidelines)
and oestrogen and progesterone receptor levels. These are some of
the prognostic factors that currently direct adjuvant therapy
administration (Goldhirsch et al, 2001). In addition, we analysed
the correlation of activity of both gelatinases with c-erbB-2
receptor level (for 46 out of 80 samples, 57.5%). As shown in
Table 1, the cancer patients displayed a variable clinical profile in
good agreement with current literature: in particular, node
involvement was demonstrated for about 40% of studied cases,
and c-erbB-2 overexpression was limited to approx. 20% patients.
As shown in Figures 3 and 4, the activity of MMP-2 and MMP-9
in the sera of breast cancer patients did not correlate with tumour
size, stage, node involvement and progesterone receptor levels.
Instead, we found a negative correlation with ER expression
(P¼0.007 for MMP-2 and 0.027 for MMP-9). By contrast, a
positive correlation was observed between gelatinolytic levels and
c-erbB-2 overexpression (P¼0.027 for MMP-2 and 0.007 for
MMP-9). Moreover, a borderline significant negative correlation
was found with nuclear grade (P¼0.0511 for MMP-2 and 0.0794
for MMP-9).
DISCUSSION
At present, the strongest predictors of breast cancer metastasis are
lymph node involvement and histological grading. These para-
meters are not enough selective to discriminate the putative
subgroup of patients within the same clinical category. In fact, it is
well documented that breast cancer patients with the same stage of
disease can have markedly different outcome and therapy
responses (van’t Veer et al, 2002). Therefore, searching for new
molecular markers is an open area of interest. In particular, the
matrix metalloproteases have since long attracted the interest of
investigators, due to their possible use as molecular markers and
therapeutic targets (cf. e.g. King et al, 2003). The majority of MMPs
are secreted as latent proenzyme forms and are subjected to
regulated activation at the cell–matrix boundary (Nagase and
Woessner, 1999). Their proenzyme forms are also secreted in body
fluids where they can be easily detected.
Several authors, including our group (Pucci-Minafra et al, 2001),
have measured the serum or plasma levels of MMP-2 and MMP-9
in oncologic patients (e.g. Garbisa et al, 1992; Zucker et al, 1993;
Hayasaka et al, 1996; Garbett et al, 1999; Oberg et al, 1999), in
some cases reaching different conclusions. One reason could be the
different pre-analytical sampling process (reviewed by Jung et al,
2001, 2002). Indeed, plasma preparation requires the addition of
anticoagulants such as EDTA or heparin, while serum is often
obtained by addition of clot accelerator. All these additives may
Breast cancer  Healthy Breast cancer  Healthy
P<0.0001 P<0.0001
900
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Figure 2 Diagrams of distribution of pro-MMP-2 (A) and pro-MMP-9 (B) activity in sera of the two groups. Values are indicated as OD for 1mg of total
serum proteins. Values of density are calculated as mean of triplicate experiments with indication of the standard error.
Table 1 Table of the clinicopathological variables assessed for primary
tumours
Factors No of patients %
Tumour size
Tis 1 1.25
T1 52 65
T2 25 31.25
T3 2 2.5
Lymph node involvement
N0 47 58.75
N1 31 38.75
N2 2 2.5
Staging
0 1 1.25
I 38 47.5
IIa 20 25
IIb 19 23.75
IIIa 2 2.5
Grading
G1 6 7.5
G1–G2 4 5
G2 44 55
G2–G3 11 13.75
G3 15 18.75
Oestrogen receptor level (76 cases)
Negative (o10%) 40 52.6
Positive (410%) 36 47.4
Progesterone receptor level (76 cases)
Negative (o10%) 41 54
Positive (410%) 35 46
cErbB-2 levels (46 cases)
0 33 71.7
1+ 4 8.7
2+ 2 4.3
3+ 7 15.3
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EDTA is a strong inhibitor of MMPs and heparin is known to bind
to some MMPs (Keller et al, 1986; Wallon and Overall, 1997). On
the other hand, serum preparation with clot accelerators can
induce platelets to release MMP-9 (Jung et al, 2001); this can be
avoided by preparing native serum in the absence of clot
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Figure 3 Correlation analysis between clinicopathological variables and progelatinase activity levels: For all variables, graphs marked with (A) indicate
correlation with pro-MMP-2, while (B) indicates pro-MMP-9. (1) Correlation with lymph node involvement; (2) correlation with tumour size; (3) correlation
with tumour staging; (4) correlation with tumour grading.
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yaccelerators, since quiescent platelets release negligible amounts of
gelatinases (Fernandez-Patron et al, 1999).
On this ground, our major aim was to study the gelatinolytic
levels of serum forms of MMP-2 and MMP-9 by zymographic
assays, and correlate data with current clinicopathological para-
meters. These zymographic tests have some advantages over
immunologic assays, due to lower costs, more rapid time of
execution and the possibility of detecting simultaneously multiple
forms of the same enzyme.
Our qualitative analysis of the zymograms showed that the
majority of the 80 sera samples from breast cancer patients
displayed sharp bands of lysis corresponding to the proenzyme
forms of MMP-2 and MMP-9, respectively, in contrast to the 22
control samples which showed less pronounced lytic bands. In
addition, the sera samples from breast cancer patients exhibited
two other lytic activities of larger molecular size, similar to those
previously identified as pro-MMP-9 dimers (200kDa) and as a
complex formed between pro-MMP-9 and its physiological
inhibitor TIMP-1 (116kDa) in colon cancer sera (Pucci-Minafra
et al, 2001). These forms were absent or very faint in the majority
of normal sera. Activated forms of both enzymes were never
detected in any sera.
The densitometric analyses indicated that the average levels of
activity of circulating MMP-2 and MMP-9 in breast cancer patients
were significantly higher than control sera (Po0.0001), and
suggest that serum measures of MMP-2 and MMP-9 activity may
have diagnostic value for discriminating subgroups of breast
cancer patients.
In order to relate our data with disease features, we applied
statistical analyses correlating activity levels of both enzymes with
clinical parameters. Univariate analysis revealed no correlation
between both gelatinases and tumour size, staging, lymph node
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Figure 4 Correlation analysis between the receptorial state of primary tumour and serum progelatinase activity levels: (A) indicates pro-MMP-2, while
(B) indicates pro-MMP-9. (1) Correlation with progesterone receptor positivity; (2) correlation with oestrogen receptor positivity; (3) correlation with c-
erbB-2 expression levels.
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observed with nuclear grading. Conversely, our data showed for
the first time an inverse correlation between ER positivity
(generally considered as a favourable prognostic factor) and
elevated levels of gelatinase activity. More interestingly, high levels
of gelatinases are significantly related to c-erbB-2 overexpression.
c-erbB-2 overexpression has been described as an independent
predictor of survival in breast cancer (Konecny et al, 2001), and its
amplification has been reported for 20–25% of breast cancer
patients (Dickson and Lippman, 1995) associated with more
aggressive clinicopathologic features (Sahin, 2000). In addition,
recent clinical investigations (Berney et al, 1998; Allgayer et al,
2000) demonstrated an association between ERBB2 overexpression
and tumour-associated proteolysis in gastric and colon
cancer, suggesting a direct role for ERBB2 in invasion and
metastasis through upregulation of proteolytic enzymes.
However, the association of ERBB2 expression with the expression
of MMP-2 and MMP-9 has not previously been reported in
breast cancer. The present data support the hypothesis that
ERBB2 amplification and/or overexpression enhance signalling
pathways that may lead to increased production of gelatinases
in c-erbB-2-positive breast cancers with higher metastatic
potentialities. With regard to biological significance, it
appears reasonable to think that the suggested network between
c-erbB-2 pathways and MMPs overexpression by in vitro models
(Giunciuglio et al, 1995) may be operative also during tumour
progression.
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